RECURSION PHARMACEUTICALS, INC. (RXRX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RXRX currently has 515M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 88.82% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 26, 2025 |
8-K filing: Recursion Pharmaceuticals, Inc. registered for resale 7,088,742 shares of its Class A common stock that were issued to Tempus AI, Inc. in payment for annual license fees. |
510M | 0 |
| Nov 05, 2025 |
10-Q filing | 514.9M shares outstanding |
510M | 0 |
| May 05, 2025 |
10-Q filing | 402.8M shares outstanding |
400M | 0 |
| Feb 28, 2025 |
10-K filing | 395.1M shares outstanding |
400M | 0 |
| Dec 17, 2024 |
8-K filing: Recursion Pharmaceuticals, Inc. filed a prospectus supplement to register for resale 3,498,393 shares of its Class A common stock that were issued to Tempus Labs, Inc. in payment for the 2024 annual license fee under the terms of a Master Agreement. |
280M | 0 |
| Nov 06, 2024 |
10-Q filing | 282.6M shares outstanding |
280M | 0 |
| Aug 08, 2024 |
10-Q filing | 273.9M shares outstanding |
270M | 0 |
| Jun 27, 2024 |
8-K filing: Recursion Pharmaceuticals, Inc. announced a public offering of 30,769,230 shares of its Class A common stock at a price of $6.50 per share, with an option for the underwriters to purchase up to an additional 4,615,384 shares. ($200.0M proceeds) |
240M | 0 |
| May 09, 2024 |
10-Q filing | 236.0M shares outstanding |
240M | 0 |
| Feb 29, 2024 |
10-K filing | 207.9M shares outstanding |
210M | 0 |
| Dec 15, 2023 |
8-K filing: Recursion Pharmaceuticals, Inc. filed a prospectus supplement to register for resale 3,225,902 shares of its Class A common stock that were issued to Tempus Labs, Inc. as payment for the initial license fee under a Master Agreement. |
210M | 0 |
| Nov 09, 2023 |
10-Q filing | 214.3M shares outstanding |
210M | 0 |
| Aug 08, 2023 |
10-Q filing | 201.4M shares outstanding |
200M | 0 |
| Jul 12, 2023 |
8-K filing: Recursion Pharmaceuticals, Inc. sold 7,706,363 shares of Class A common stock to NVIDIA Corporation in a private placement at a price of $6.488145 per share, resulting in gross proceeds of approximately $50 million. ($50.0M proceeds) |
190M | 0 |
| May 08, 2023 |
8-K filing: Recursion Pharmaceuticals, Inc. entered into agreements to acquire Cyclica Inc. and Valence Discovery Inc., paying consideration in the form of Recursion Class A common stock. ($87.5M proceeds) |
180M | 0 |
| May 08, 2023 |
10-Q filing | 191.6M shares outstanding |
190M | 0 |
| Feb 27, 2023 |
10-K filing | 175.5M shares outstanding |
180M | 0 |
| Nov 08, 2022 |
10-Q filing | 173.4M shares outstanding |
170M | 0 |
| Aug 09, 2022 |
10-Q filing | 172.2M shares outstanding |
170M | 0 |
| May 10, 2022 |
10-Q filing | 170.7M shares outstanding |
170M | 0 |
| Mar 23, 2022 |
10-K filing | 161.8M shares outstanding |
160M | 0 |
| Nov 10, 2021 |
10-Q filing | 168.5M shares outstanding |
170M | 0 |
| Aug 13, 2021 |
10-Q filing | 159.0M shares outstanding |
160M | 0 |
| May 12, 2021 |
10-Q filing | 168.3M shares outstanding |
170M | 0 |
| Mar 22, 2021 |
S-1 filing: Recursion Pharmaceuticals, Inc. is offering shares of its Class A common stock in an initial public offering. |
N/A | 0 |